An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants
- Conditions
- Basal Cell Carcinoma
- Registration Number
- NCT02100111
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This multi-center, observational study involves reviewing the medical records of approximately 100 adult participants diagnosed with advanced BCC from 01 January 2005 until 31 December 2010. Participant records will be analyzed to identify participant characteristics, treatment patterns and clinical outcomes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 134
- New diagnosis of advanced BCC, defined as (1) locally advanced BCC (inoperable as determined by the site investigator or surgery contraindicated) with receipt of radiation therapy (unless radiation was contraindicated), or (2) metastatic BCC, from 01 January 2005 through 31 December 2010
- Participation in an interventional trial that dictated treatment during the study time period (01 January 2005 - 31 December 2010), or within 90 days prior to individual participant' study enrolment dates
- Participants undergoing treatment with a Hedgehog pathway inhibitor
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Participants Demographics: Age at Initation of Study Baseline (Initiation of the study) Participants Demographics: Gender at Initation of Study Baseline Participants Demographics: Race at Initation of Study Baseline Participants Demographics: Country of Enrollment at Initation of Study Baseline Percentage of Participants Categorized as per BCC Disease History Baseline up to 9 months Percentage of Participants Categorized as per BCC Type Baseline up to 9 months Percentage of Participants Categorized as per Site of Primary Lesion Baseline up to 9 months Percentage of Participants Categorized as per Number of Lesions Baseline up to 9 months Percentage of Participants Categorized as per Size of Lesions Baseline up to 9 months Percentage of Participants Categorized as per Histopathology of BCC Baseline up to 9 months Percentage of Participants Categorized as per Basal Cell Carcinoma Nevus Syndrome (BCCNS) Status Baseline up to 9 months Percentage of Participants Categorized as per Eastern Cooperative Oncology Group (ECOG) Performance Status Baseline up to 9 months Percentage of Participants Categorized as per Number of Biopsies Undergone Baseline up to 9 months Percentage of Participants Categorized as per Type of BCC Treatment Received Baseline up to 9 months Percentage of Participants With Complete Response Baseline up to 9 months Percentage of Participants Who Died Baseline up to event of death assessed maximum up to 9 months Percentage of Participants With Progression Free survival Baseline up to 9 months Percentage of Participants Categorized as per Impact of Surgery for BCC on Organ Function Baseline up to 9 months Percentage of Participants With Partial Response Baseline up to 9 months Percentage of Participants With Stable Disease Baseline up to 9 months Percentage of Participants With Disease Progression Baseline up to 9 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (42)
Hotel Dieu; Dermatologie
🇫🇷Angers, France
Hopital Prive D Antony; Dermatologie
🇫🇷Antony, France
Hôpital St Jacques de Besançon; (Dermatology)
🇫🇷Besançon, France
Hopital Saint Andre CHU De Bordeaux; Dermatologie
🇫🇷Bordeaux, France
Hopital Ambroise Pare; Sce Dermatologie
🇫🇷Boulogne-billancourt, France
Hopital La Cavale Blanche; Medecine 1
🇫🇷Brest, France
Chu Estaing; Dermatologie
🇫🇷Clermont Ferrand, France
Hopital Victor Jousselin; Dermatologie
🇫🇷Dreux, France
Chi Emile Durkheim Site Epinal; Oncologie
🇫🇷Epinal, France
Hôpital Albert Michallon; Derm Phlebologie Allergologie
🇫🇷Grenoble, France
Scroll for more (32 remaining)Hotel Dieu; Dermatologie🇫🇷Angers, France